ReviewNature reviews. Cancer2012
Unmasking the immune recognition of prostate cancer with CTLA4 blockade.
Review in Nature reviews. Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus.Arthritis research & therapy · 2018Pooled it
- Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial.Cancer immunology, immunotherapy : CII · 2021Trial
- MYC promotes the progression of prostate cancer by regulating CD47 to induce an immunosuppressive microenvironment.Cellular and molecular life sciences : CMLS · 2026Article
- Breaching the immune-cold barrier in pMMR/MSS metastatic colorectal cancer: emerging strategies beyond standard care.Frontiers in immunology · 2026Review
- Overcoming Immune Evasion in the Prostate Tumor Microenvironment: Novel Targeted Strategies to Improve Treatment Outcomes.Cancers · 2025Review
- Components of the Endosome-Lysosome Vesicular Machinery as Drivers of the Metastatic Cascade in Prostate Cancer.Cancers · 2024Review
- Correlation analysis between immune-related genes and cell infiltration revealed prostate cancer immunotherapy biomarkers linked to T cells gamma delta.Scientific reports · 2023Article
- Engineering magnetic nano-manipulators for boosting cancer immunotherapy.Journal of nanobiotechnology · 2022Review
- RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion.Journal of experimental & clinical cancer research : CR · 2022Article
- Cross-Activation of Hemichannels/Gap Junctions and Immunoglobulin-Like Domains in Innate-Adaptive Immune Responses.Frontiers in immunology · 2022Review
- MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.International journal of general medicine · 2022Article
- RNA expression differences in prostate tumors and tumor-adjacent stroma between Black and White Americans.Oncotarget · 2021Article
- Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome.Journal for immunotherapy of cancer · 2020Article
- Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature.Journal of translational medicine · 2020Article
- Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study.Frontiers in oncology · 2020Article
- Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.Frontiers in immunology · 2020Article
- Microalgae with Immunomodulatory Activities.Marine drugs · 2019Review
- rs4143815-International journal of molecular sciences · 2019Article
- Potentiating prostate cancer immunotherapy with oncolytic viruses.Nature reviews. Urology · 2018Review
- Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.Urologic oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Although cancer cells can be immunogenic, tumour progression is associated with the evasion of immunosurveillance, the promotion of tumour tolerance and even the production of pro-tumorigenic factors by immune cells. Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) represents a crucial immune checkpoint, the blockade of which can potentiate anti-tumour immunity. CTLA4-blocking antibodies are now an established therapeutic approach for malignant melanoma, and clinical trials with CTLA4-specific antibodies in prostate cancer have also shown clinical activity. This treatment may provide insights into the targets that the immune system recognizes to drive tumour regression, and could potentially improve both outcome and toxicity for patients with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.